Translate this page to:
In JoVE (1)
- Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Other Publications (2)
Articles by Joanne L Fothergill in JoVE
Use of Artificial Sputum Medium to Test Antibiotic Efficacy Against Pseudomonas aeruginosa in Conditions More Relevant to the Cystic Fibrosis Lung
Sebastian Kirchner1, Joanne L Fothergill2, Elli A. Wright1, Chloe E. James1, Eilidh Mowat1, Craig Winstanley1
1Institute of Infection and Global Health, University of Liverpool, 2NIHR Biomedical Research Centre in Microbial Disease, University of Liverpool
Current diagnostic antimicrobial susceptibility testing relies on the planktonic growth of isolates in nutrient rich, aerobic conditions. Here, we employ an alternative artificial sputum medium to study antimicrobial susceptibility of Pseudomonas aeruginosa biofilms under both aerobic and microaerophilic conditions more representative of the cystic fibrosis lung.
Other articles by Joanne L Fothergill on PubMed
A Subtype of a Pseudomonas Aeruginosa Cystic Fibrosis Epidemic Strain Exhibits Enhanced Virulence in a Murine Model of Acute Respiratory Infection
The Journal of Infectious Diseases. Sep, 2010 | Pubmed ID: 20704484
The Liverpool epidemic strain (LES) of Pseudomonas aeruginosa is a particularly successful cystic fibrosis (CF) pathogen associated with transmissibility, increased patient morbidity, and, unusually, infection of the non-CF parents of a patient with CF.
Expert Review of Anti-infective Therapy. Feb, 2012 | Pubmed ID: 22339195
Pseudomonas aeruginosa is a highly successful opportunistic pathogen that displays intrinsic multidrug resistance and has a tremendous capacity to acquire further resistance mechanisms. During chronic infection, the bacterium can form a protective biofilm therefore reducing the efficacy of existing antibiotics. P. aeruginosa also harbors an impressive range of virulence factors, many of which are controlled by the quorum-sensing system. Several novel therapeutics are under investigation such as those directed against biofilm formation and quorum-sensing systems along with bacteriophages and immunotherapies. Recent advances in next-generation sequencing and comparative genomics have opened the door to a new wave of smart drug design that could revolutionize P. aeruginosa treatment options.